|13.03||-0.04 / -0.31%|
As of 3:59pm ET
|13.03||0.00 / 0.00%|
The 7 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 20.00, with a high estimate of 21.00 and a low estimate of 11.00. The median estimate represents a +53.49% increase from the last price of 13.03.
The current consensus among 8 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.